Philip Ashton-Rickardt - 01 Jul 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Jul 2021
Net transactions value
$0
Form type
4
Filing time
02 Jul 2021, 16:10:35 UTC
Previous filing
14 Jun 2021
Next filing
04 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +90,000 $0.000000 90,000 01 Jul 2021 Common Stock 90,000 $10.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vest as to 25% of the underlying shares of common stock on June 14, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.